Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

This study evaluates the cost-effectiveness of HER2/neu 655 genotyping. Methods: Eighty-eight HER2-positive breast cancer patients treated for early disease with trastuzumab were retrospectively ...

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s ...

The FDA has expanded the label for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody. This enables the identification of patients with hormone receptor (HR)-positive, HER2-ultralow ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment. The FDA has expanded the label for the ...

Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit ...

FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer — T-DXd approved in metastatic HR-positive, HER2-low/ultralow disease following endocrine therapy ...

Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.

PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has been approved by the FDA as a companion diagnostic for zanidatamab-hrii (Ziihera) to assess HER2-positive (HER2+) status in patients ...